GlycoBac

Cover Block

Attribute	Details
Company Name	GlycoBac
Tagline	Provides glycoengineered insect cell platforms and tools for biologics production and research.
Headquarters	Laramie, WY, USA
Founded	2011
Stage	Other
Business Model	B2B
Industry	Deeptech
Technology Type	Biotech / Life Sciences
Geography	North America
Founding Team	Academic Spinout (University of Wyoming)
Funding Label	Undisclosed (total disclosed ~$259,284)
Total Disclosed Funding	~$259,284 [NIH RePORT, 2022]

Links

• Website: https://www.glycobac.com/
• LinkedIn: https://linkedin.com/in/donald-jarvis-4bb35a2

What an Investor Needs First

GlycoBac provides a specialized, glycoengineered insect cell platform for the production of biologics [GlycoBac, retrieved 2024]. Founded in 2011 as an academic spinout from the University of Wyoming, the company has spent over a decade developing proprietary cell lines and baculovirus vectors designed to produce therapeutic proteins with human-like sugar structures [BioProcess International On-Demand Speaker, 2026]. Its core offering includes research tools like expression plasmids priced at $300 each and contract services for lab-scale production [GlycoBac, retrieved 2024].

The company's intellectual foundation is anchored by Dr. Donald L. Jarvis, a virology PhD and professor whose research on the baculovirus-insect cell system spans nearly 25 years, with key patents exclusively licensed to GlycoBac [Grantome, retrieved 2026]. To date, its capitalization appears limited to non-dilutive grant funding, including a documented $259,284 award from the NIH in 2022 [NIH RePORT, 2022]. Over the next 12-18 months, the primary indicators to monitor are any transition from grant-funded research to announced commercial partnerships or licensing deals.

Data Accuracy: YELLOW -- Core technology and team details are confirmed by primary sources; funding and commercial status rely on limited public records.

Taxonomy Snapshot

Axis	Classification
Stage	Other
Business Model	B2B
Industry / Vertical	Biotech / Life Sciences
Technology Type	Biotech / Life Sciences
Geography	North America
Founding Team	Academic Spinout

Inside the Company

GlycoBac, LLC was founded in 2011 as a Wyoming-based biotechnology company, emerging from over two decades of academic research at the University of Wyoming [GlycoBac, retrieved 2024]. The company's origin is directly tied to the work of Dr. Donald L. Jarvis, a professor of molecular biology whose research into the baculovirus-insect cell system began in 1987 [BioProcess International On-Demand Speaker, 2026]. The firm operates from the Wyoming Technology Business Center on the university's campus in Laramie [GlycoBac, retrieved 2024].

From its inception, the company's trajectory has been defined by grant-funded research and development. A key early milestone was securing an exclusive license to intellectual property covering glycoengineered baculovirus-insect cell systems [Grantome, retrieved 2026]. The company has received at least one documented grant from the National Institutes of Health, valued at $259,284, awarded in 2022 [NIH RePORT, 2022]. Its primary commercial activities involve providing engineered cell lines, vectors, and plasmids to the global research community, alongside offering lab-scale production and characterization services [GlycoBac, retrieved 2024].

Public records present a mixed picture of the company's current operational status. While its website remains active and lists Dr. Jarvis as President, a third-party commercial database flagged the company as "deadpooled" as of June 2022 [Tracxn, retrieved 2024].

Data Accuracy: YELLOW -- Key founding details and location confirmed by company website and academic sources; operational status is conflicted between primary and third-party sources.

Under the Hood

GlycoBac’s commercial offering is a suite of research tools and contract services built around its proprietary glycoengineered insect cell platform. The core proposition is that standard insect cell systems produce biologics with sugars incompatible for human therapeutics; GlycoBac’s engineered cells are designed to add the correct, human-like sugar structures [GlycoBac, retrieved 2024].

The product catalog is split into discrete, purchasable components and bespoke services. For direct sale, the company lists expression plasmids, pIE1HRX, pIE1HRX-Neo, and pIE1HRX-Hygro, for $300 each, including shipping [GlycoBac, retrieved 2024]. It also provides engineered insect cell lines and baculovirus vectors. A key technical milestone is the development of the Sf-RVN cell line, a virus-free isolate intended to improve manufacturing consistency and safety [BioProcess International On-Demand Speaker, 2026] [Glycobiology.org, 2023]. On the service side, GlycoBac offers lab-scale biologic production and characterization experiments, along with education and training for applying its platform [GlycoBac, retrieved 2024].

The technology’s claimed advantages are specificity and control. The company states its platform can produce biologics with “specific sugar structures,” is “fully scalable,” and is protected by an exclusive license to key intellectual property for glycoengineered Baculovirus-Insect Cell Systems (BICS) [GlycoBac, retrieved 2024] [Grantome, retrieved 2026].

Data Accuracy: GREEN -- Product details and technical claims are confirmed by the company's website and cited academic presentations.

Competition and Substitutes

GlycoBac operates in a niche defined by its specific production platform. The competitive analysis maps the broader ecosystem of biologics production platforms, where GlycoBac’s technology represents one alternative among several established paths.

• Mammalian cell culture. This is the dominant, industry-standard platform for producing complex therapeutic proteins. Systems using Chinese Hamster Ovary (CHO) cells are favored for their ability to produce human-like glycosylation patterns.
• Other non-mammalian platforms. Competing alternative platforms include microbial systems (E. coli, yeast) for simpler proteins, and plant-based systems.
• Academic and research tools. The market for research-grade plasmids, cell lines, and vectors is crowded with large suppliers like Thermo Fisher Scientific and numerous smaller biotech vendors. GlycoBac’s sale of expression plasmids for $300 each places it in this segment [GlycoBac, retrieved 2024].

GlycoBac’s defensible edge rests on its exclusive license to key intellectual property for glycoengineered baculovirus-insect cell systems (BICS) and its foundational academic research [Grantome, retrieved 2026]. This IP, stemming from nearly 25 years of work by Dr. Donald Jarvis’s team, covers the engineering of insect cells to produce human-like glycans.

Data Accuracy: YELLOW -- Competitive mapping is inferred from public descriptions of the biologics production landscape; no direct competitor names are confirmed in sources.

Opportunity

The ultimate prize for GlycoBac is establishing its glycoengineered insect cell platform as a new, widely adopted standard for producing complex biologic drugs.

Scenario	What happens	Catalyst	Why it's plausible
Research Tool Standardization	GlycoBac's plasmids and virus-free cell lines become ubiquitous in academic and early-stage biotech labs.	A major research consortium or a leading pharmaceutical company adopts the platform for its internal discovery work.	The company already sells standardized plasmids at a fixed price and provides training [GlycoBac, retrieved 2024].
Process Licensing for Commercial Production	Biopharma companies license GlycoBac's engineered cell lines and processes for the GMP manufacturing of a specific, high-value biologic.	Successful completion of a lab-scale production run for a partner's clinical candidate.	The company explicitly offers lab-scale production and characterization services [GlycoBac, retrieved 2024].

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated capabilities and commercial offerings, which are well-documented. The plausibility of growth scenarios is inferred from the company's business model and cited academic adoption, but lacks third-party validation of commercial partnerships or scaling.

Sources

1. [GlycoBac, retrieved 2024] GlycoBac - glycoengineered baculovirus insect cell platforms... | https://www.glycobac.com/
2. [BioProcess International On-Demand Speaker, 2026] Don Jarvis - GlycoBac, LLC | BioProcess International On-Demand Speaker | https://informaconnect.com/bioprocess-international-on-demand/speakers/don-jarvis/
3. [Grantome, retrieved 2026] GlycoBac | https://grantome.com/grant/NIH/R43-GM088893-01
4. [NIH RePORT, 2022] NIH RePORT entry for GlycoBac | https://reporter.nih.gov/search/5sP8l5KfE0KdNf5Yv6pVYw/project-details/10505658
5. [Tracxn, retrieved 2024] GlycoBac | https://platform.tracxn.com/a/d/company/58bdaa9ce4b041de9c7f72eb/glycobac?utm_source=parallel&utm_medium=ai#a:about
6. [Glycobiology.org, 2023] 2023 Rosalind Kornfeld Award for Lifetime Achievement... | https://www.glycobiology.org/rk_2023_jarvis